|
57 Products |
| 57 Products |
|
190 Diseases |  |
11246 News |  |
| «12...9899100101102103104105106107108...109110» |
- amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Enrollment closed: Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients (clinicaltrials.gov) - Jan 30, 2017
P1, N=17, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting --> Active, not recruiting
- cenerimod (ACT-334441) / Idorsia
Trial completion: A Study to Evaluate Cenerimod in Healthy Male Subjects (clinicaltrials.gov) - Jan 17, 2017
P1, N=6, Completed, Sponsor: Actelion
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Enrollment closed, Real-world evidence, Real-world: EFFECT: Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jan 13, 2017
P=N/A, N=2978, Active, not recruiting, Sponsor: Biogen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||| Zeposia (ozanimod) / BMS
Enrollment open: DAYBREAK: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis (clinicaltrials.gov) - Dec 22, 2016
P3, N=2350, Enrolling by invitation, Sponsor: Celgene
Recruiting --> Active, not recruiting Active, not recruiting --> Enrolling by invitation
- fingolimod / Generic mfg.
Trial primary completion date: Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod (clinicaltrials.gov) - Dec 21, 2016
P=N/A, N=40, Recruiting, Sponsor: Charite University, Berlin, Germany
Active, not recruiting --> Enrolling by invitation Trial primary completion date: Mar 2016 --> Nov 2017
- fingolimod / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) (clinicaltrials.gov) - Dec 21, 2016
P2/3, N=8, Terminated, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Mar 2016 --> Nov 2017 N=88 --> 8 | Recruiting --> Terminated | Trial primary completion date: Apr 2017 --> Apr 2016; delayed recruitment
- Zeposia (ozanimod) / BMS
New P1 trial: A Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults (clinicaltrials.gov) - Dec 15, 2016
P1, N=6, Completed, Sponsor: Celgene Corporation
- | Ponvory (ponesimod) / Juvise Pharma, Vanda
Enrollment closed, Trial initiation date: Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD (clinicaltrials.gov) - Dec 12, 2016
P2, N=30, Active, not recruiting, Sponsor: Actelion
N=88 --> 8 | Recruiting --> Terminated | Trial primary completion date: Apr 2017 --> Apr 2016; delayed recruitment Recruiting --> Active, not recruiting | Initiation date: Jun 2016 --> Feb 2016
- cenerimod (ACT-334441) / Idorsia
Enrollment closed: A Study to Evaluate Cenerimod in Healthy Male Subjects (clinicaltrials.gov) - Nov 22, 2016
P1, N=6, Active, not recruiting, Sponsor: Actelion
Recruiting --> Active, not recruiting | Initiation date: Jun 2016 --> Feb 2016 Recruiting --> Active, not recruiting
- ||||||| Trial completion: Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation (clinicaltrials.gov) - Nov 17, 2016
P3, N=140, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting No longer recruiting --> Completed
- ||||||| Trial completion: Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. (clinicaltrials.gov) - Nov 15, 2016
P3, N=106, Completed, Sponsor: Novartis Pharmaceuticals
No longer recruiting --> Completed Active, not recruiting --> Completed
- |||| fingolimod / Generic mfg.
Trial primary completion date: PARADIGMS: Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis (clinicaltrials.gov) - Nov 14, 2016
P3, N=190, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Aug 2022 --> Mar 2023
- ||| cenerimod (ACT-334441) / Idorsia
Enrollment closed: Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - Nov 14, 2016
P2, N=64, Active, not recruiting, Sponsor: Actelion
Trial primary completion date: Aug 2022 --> Mar 2023 Recruiting --> Active, not recruiting
- cenerimod (ACT-334441) / Idorsia
Trial primary completion date: Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441 (clinicaltrials.gov) - Nov 8, 2016
P1, N=32, Terminated, Sponsor: Actelion
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> May 2016
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P2 trial: FAMTAIS: Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke (clinicaltrials.gov) - Nov 7, 2016
P2, N=96, Not yet recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
- ||| icanbelimod (CBP-307) / Suzhou Connect Biopharma
Trial completion, Trial primary completion date: Phase 1 Study Accessing the Safety and Tolerability of CBP-307 (clinicaltrials.gov) - Nov 3, 2016
P1, N=64, Completed, Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.
Trial primary completion date: Dec 2016 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> Aug 2015
- |||| Mayzent (siponimod) / Novartis
Trial primary completion date: Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) (clinicaltrials.gov) - Oct 27, 2016
P3, N=1652, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> Aug 2015 Trial primary completion date: Aug 2017 --> Dec 2020
- ||| fingolimod / Generic mfg.
Enrollment closed, Trial primary completion date: PASSOS: A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya (clinicaltrials.gov) - Oct 27, 2016
P4, N=88, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2017 --> Dec 2020 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Jan 2019
- | Mayzent (siponimod) / Novartis
Trial completion: Efficacy and Tolerability of BAF312 in Patients With Polymyositis (clinicaltrials.gov) - Oct 27, 2016
P2, N=14, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Jan 2019 Terminated --> Completed
- glatiramer acetate / Generic mfg., fingolimod / Generic mfg.
Enrollment closed, Enrollment change, HEOR, Patient reported outcomes: Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate (clinicaltrials.gov) - Oct 26, 2016
P=N/A, N=157, Active, not recruiting, Sponsor: University of Colorado, Denver
Terminated --> Completed Recruiting --> Active, not recruiting | N=120 --> 157
- cenerimod (ACT-334441) / Idorsia
Enrollment open: A Study to Evaluate Cenerimod in Healthy Male Subjects (clinicaltrials.gov) - Oct 25, 2016
P1, N=6, Recruiting, Sponsor: Actelion
Recruiting --> Active, not recruiting | N=120 --> 157 Not yet recruiting --> Recruiting
- Veyonda (idronoxil) / Noxopharm
New P2a trial, Combination therapy, Monotherapy: Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours (clinicaltrials.gov) - Oct 20, 2016
P2a, N=35, Not yet recruiting, Sponsor: Noxopharm Limited
- New P2/3 trial: Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients (clinicaltrials.gov) - Oct 18, 2016
P2/3, N=50, Completed, Sponsor: Isfahan University of Medical Sciences
- | amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Enrollment closed, Enrollment change: Extension Study of MT-1303 in Subjects With Crohn's Disease (clinicaltrials.gov) - Oct 14, 2016
P2, N=46, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=80 --> 46
- |||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Trial completion: Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease (clinicaltrials.gov) - Oct 14, 2016
P2, N=78, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting --> Active, not recruiting | N=80 --> 46 Recruiting --> Completed
- Mayzent (siponimod) / Novartis
Enrollment change, Trial termination, Trial primary completion date: Efficacy and Tolerability of BAF312 in Patients With Polymyositis (clinicaltrials.gov) - Oct 11, 2016
P2, N=14, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed N=45 --> 14 | Recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Aug 2016
- Zeposia (ozanimod) / BMS
Enrollment open: Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS (clinicaltrials.gov) - Sep 30, 2016
P1, N=24, Recruiting, Sponsor: Celgene
N=45 --> 14 | Recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Aug 2016 Not yet recruiting --> Recruiting
- |||| Zeposia (ozanimod) / BMS
Trial primary completion date: SUNBEAM: Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) (clinicaltrials.gov) - Sep 28, 2016
P3, N=1200, Active, not recruiting, Sponsor: Celgene
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2017 --> Dec 2016
- cenerimod (ACT-334441) / Idorsia
New P1 trial: A Study to Evaluate Cenerimod in Healthy Male Subjects (clinicaltrials.gov) - Sep 26, 2016
P1, N=6, Not yet recruiting, Sponsor: Actelion
- || Trial primary completion date: EARLiMS: Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy (clinicaltrials.gov) - Sep 23, 2016
P4, N=434, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2017 --> Dec 2016 Trial primary completion date: Jul 2016 --> Oct 2016
- |||||||||| Ponvory (ponesimod) / J&J
New P3 trial, Head-to-Head: POINT: Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera (clinicaltrials.gov) - Sep 20, 2016
P3, N=600, Not yet recruiting, Sponsor: Actelion
- amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Trial primary completion date: Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients (clinicaltrials.gov) - Sep 19, 2016
P1, N=18, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Trial primary completion date: Jul 2016 --> Oct 2016 Trial primary completion date: Jan 2017 --> Apr 2017
- Enrollment closed: FINGORETT: Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome (clinicaltrials.gov) - Sep 14, 2016
P1/2, N=6, Active, not recruiting, Sponsor: University Hospital, Basel, Switzerland
Trial primary completion date: Jan 2017 --> Apr 2017 Recruiting --> Active, not recruiting
- | Tysabri (natalizumab) / Biogen, Royalty
Trial completion, Enrollment change, Trial primary completion date, IO biomarker: Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod (clinicaltrials.gov) - Sep 14, 2016
P=N/A, N=25, Completed, Sponsor: University Hospital, Basel, Switzerland
Recruiting --> Active, not recruiting Recruiting --> Completed | N=40 --> 25 | Trial primary completion date: Dec 2016 --> Aug 2016
- BXQ-350 / Bexion
Enrollment open, Metastases: Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Sep 13, 2016
P1, N=40, Recruiting, Sponsor: Bexion Pharmaceuticals, LLC.
Recruiting --> Completed | N=40 --> 25 | Trial primary completion date: Dec 2016 --> Aug 2016 Not yet recruiting --> Recruiting
- ||| Zeposia (ozanimod) / BMS
Biomarker, Enrollment closed: Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Aug 29, 2016
P2, N=60, Active, not recruiting, Sponsor: Celgene
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial primary completion date: A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma (clinicaltrials.gov) - Aug 25, 2016
P0, N=5, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Jun 2017
- || BMS-986166 / BMS
Trial primary completion date: A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects (clinicaltrials.gov) - Aug 24, 2016
P1, N=66, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Apr 2017 --> Oct 2017
- |||| Mayzent (siponimod) / Novartis
Enrollment open, Enrollment change: Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Aug 23, 2016
P2, N=250, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Apr 2017 --> Oct 2017 Active, not recruiting --> Recruiting | N=186 --> 250
- |||| Biomarker, Enrollment open, Trial primary completion date, IO biomarker: Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) (clinicaltrials.gov) - Aug 23, 2016
P4, N=150, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting | N=186 --> 250 Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Oct 2016
- | Ponvory (ponesimod) / Juvise Pharma, Vanda
Enrollment open: Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD (clinicaltrials.gov) - Aug 19, 2016
P2, N=30, Recruiting, Sponsor: Actelion
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Oct 2016 Not yet recruiting --> Recruiting
- || Trial primary completion date: STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START) (clinicaltrials.gov) - Aug 12, 2016
P4, N=7000, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2016 --> Dec 2016
- | BXQ-350 / Bexion
New P1 trial, Metastases: Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 9, 2016
P1, N=40, Not yet recruiting, Sponsor: Bexion Pharmaceuticals, LLC.
- ||| BMS-986166 / BMS
Enrollment open: A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects (clinicaltrials.gov) - Aug 9, 2016
P1, N=66, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Aug 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- || Trial primary completion date: MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone (clinicaltrials.gov) - Aug 8, 2016
P4, N=1960, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2023 --> Mar 2022
- ||| Enrollment open, Real-world evidence, Real-world: EFFECT: Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Aug 3, 2016
P=N/A, N=3000, Recruiting, Sponsor: Biogen
Trial primary completion date: Jun 2023 --> Mar 2022 Not yet recruiting --> Recruiting
- Enrollment closed, Trial primary completion date: Fingolimod in Schizophrenia Patients (clinicaltrials.gov) - Jul 28, 2016
P2, N=40, Active, not recruiting, Sponsor: Indiana University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Aug 2016
- || Trial primary completion date: EARLiMS: Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy (clinicaltrials.gov) - Jul 20, 2016
P4, N=434, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Aug 2016 Trial primary completion date: Mar 2016 --> Jul 2016
- Mayzent (siponimod) / Novartis
Trial primary completion date: Efficacy and Tolerability of BAF312 in Patients With Polymyositis (clinicaltrials.gov) - Jul 19, 2016
P2, N=45, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2016 --> Jul 2016 Trial primary completion date: Dec 2016 --> Jul 2017
- New trial, Real-world evidence, Real-world: Fingolimod Real World Experience: the French Grand-Est Cohort (clinicaltrials.gov) - Jun 15, 2016
P=N/A, N=1014, Completed, Sponsor: CHU de Reims